Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434922 | 0.81 | CA12 (0.36) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL7238042 | 0.78 | HSP90AA1 (0.34) | MEN1KMT2ACA12CA1CA9 | |
| SCHEMBL5356463 | 0.77 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL5362365 | 0.77 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL5356460 | 0.77 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL6437495 | 0.77 | CA12 (0.38) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL6437156 | 0.77 | CA12 (0.38) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL5360953 | 0.77 | CA12 (0.44) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL6804163 | 0.74 | CA12 (0.40) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL6433944 | 0.73 | CA12 (0.39) | CA12CA1CA9HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282592-B2 | Resorcinol derivatives | WARNER-LAMBERT COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070122367-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7173052-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | BRADLEY STUART E | 2005-12-22 | — | — | US | disclosed |
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6590105-B2 | For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits | WARNER-LAMBERT COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122367-A1 | RESORCINOL DERIVATIVES | LRAT, NQO1, ALDH1A2 | MEN1 2440/4885KMT2A 2259/4885CA12 4635/4885 |
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | MEN1 2493/4885KMT2A 2172/4885CA12 4452/4885 |
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | MEN1 2440/4885KMT2A 2259/4885CA12 4635/4885 |
| US-20030180236-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | MEN1 2440/4885KMT2A 2259/4885CA12 4635/4885 |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | RBP4, NQO1, ALDH1A2 | MEN1 3029/4885KMT2A 771/4885CA12 3704/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | MEN1 2493/4885KMT2A 2172/4885CA12 4452/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | MEN1 2440/4885KMT2A 2259/4885CA12 4635/4885 |
| US-20020114770-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | MEN1 2440/4885KMT2A 2259/4885CA12 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.